

<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371</b>		ATTORNEY'S DOCKET NUMBER  NC-10006/US
U.S. APPLICATION NO. (if known) <div style="font-size: 2em; font-weight: bold; text-align: center;">10/591895</div>		PRIORITY DATE CLAIMED 08 March 2004
INTERNATIONAL APPLICATION NO. PCT/GB2005/000885	INTERNATIONAL FILING DATE 08 March 2005	
TITLE OF INVENTION <b>PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES</b>		
APPLICANT(S) FOR DO/EO/US <b>PROSIDION LIMITED</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing 35 U.S.C. 371</li> <li>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371 (f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> <li>4. <input type="checkbox"/> The US has been elected (PCT Article 31).</li> <li>5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c)(2))           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</li> <li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</li> </ol>		
<b>Items 11 to 20 below concern document(s) or information included:</b>		
<ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input checked="" type="checkbox"/> A preliminary amendment.</li> <li>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</li> <li>15. <input type="checkbox"/> A substitute specification.</li> <li>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</li> <li>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.</li> <li>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</li> <li>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li>20. Other items or information: International Published Application, International Search Report and International Preliminary Report</li> </ol>		

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
10/591895		PCT/GB2005/000885		NC-10006/US	
The following fees are submitted:				CALCULATIONS PTO USE ONLY	
21. Basic National Fee (37 CFR 1.492(a)) .....				\$	300.00
22. Examination Fee (37 CFR 1.492(c))				\$	200.00
If the written opinion prepared by the ISA/US or in the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4) ....				\$	0.00
All other situations .....				\$	200.00
23. Search Fee (37 CFR 1.492(b))				\$	400.00
If the written opinion prepared of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4) .....				\$	0.00
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority .....				\$	100.00
International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB .....				\$	400.00
All other situations .....				\$	500.00
TOTAL OF 21, 22 AND 23 =				\$	900.00
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)).					
The fee is \$250.00 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	Rate		
-100	/50		x \$250	\$	0.00
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h))				\$	0.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	18 - 20 =	0	x 50.00	\$	
Independent claims	3 - 3 =	0	x 200.00	\$	
MULTIPLE DEPENDENT CLAIM(s) (if applicable)			+ 360.00	\$	
TOTAL OF CLAIM CALCULATIONS =				\$	
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	0.00
SUBTOTAL =				\$	900.00
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					0.00
TOTAL NATIONAL FEE =				\$	900.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The Assignment must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31) (\$ 40.00 per property).				\$	0.00
TOTAL FEES ENCLOSED =				\$	900.00
Amount to be Refunded:				\$	
Charged:				\$	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a.	<input type="checkbox"/>	A check in the amount of \$_____ to cover the above fees is enclosed.
b.	<input checked="" type="checkbox"/>	Please charge my Deposit Account No. 502783 in the amount of \$900.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
c.	<input checked="" type="checkbox"/>	The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to my Deposit Account No. 502783. A duplicate copy of this sheet is enclosed.
d.	<input type="checkbox"/>	Fees are to be charged to a credit card. Provide credit card information and authorization on PTO-2038.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.**

Send all correspondence to:

Mr. Shu M. Lee  
Attorney for Applicant  
Registration No. 41,147  
CUSTOMER NUMBER 38724  
OSI Pharmaceuticals, Inc.  
41 Pinelawn Road  
Melville, New York 11747  
Telephone: (631) 962-2000  
Facsimile: (631) 845-0582

  
\_\_\_\_\_  
SIGNATURE

Shu M. Lee

NAME

41,147

REGISTRATION NUMBER

10/591895

Express Mail No.: EQ522588573US  
NC-10006/US

IAP9 Rec'd PCT/PTO 07 SEP 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): PROSIDION LIMITED

International  
Application No.: PCT/GB2005/000885

International  
Filing Date: March 8, 2005

Priority Date: March 8, 2004

For: PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 CFR § 1.10**

MAIL STOP PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

"Express Mail" mailing number: EQ522588573US

Date of Deposit: September 7, 2006

**The Following Has Been Deposited:**

- 1) Transmittal letter to the United States Designated/Elected Office (DO/EO/US) concerning a filing under 35 USC 371;
- 2) International Published Application WO 2005/085245 A1;
- 3) International Search Report;
- 4) International Preliminary Report;
- 5) Declaration of Inventors;
- 6) Preliminary Amendment; and
- 7) Return Postcard

I hereby certify that all enclosures listed above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10 on the date indicated below and is addressed to the Assistant Commissioner for Patents, Mail Stop PCT, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit: SEPTEMBER 7, 2006

Signature of Person Mailing: 

Printed Name of Person Mailing: ANNA DUSHINE

Respectfully submitted,

Dated: 07 Sept. 2006



Mr. Shu M. Lee  
Attorney for Applicant  
Registration No. 41,147  
CUSTOMER NUMBER 38724  
OSI Pharmaceuticals, Inc.  
41 Pinelawn Road  
Melville, New York 11747  
Telephone: (631) 962-2000  
Facsimile: (631) 845-0582